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Introduction 
It has been known for many years that the evolution 
of cancer is a multi-step process [for review see (1) and 
references therein]. Insight into the nature of some 
of the steps has been gained through advances in mol- 
ecular and cellular biology and it has become apparent 
that mutations in a limited number of genes which 
control cell proliferation and differentiation is a key 
feature of this process. Two categories of genes in 
particular have been implicated: proto- oncogenes and 
tumour-suppressor genes [for review see (2)]. Proto- 
oncogenes become ‘activated to oncogenes through 
particular mutations so that either the normal protein 
is overexpressed or a mutant protein is produced. 
Expression of tumour suppressor genes is believed 
to restrain cells from unregulated proliferation and 
inactivation of both homologues releases cells from 
these controls. 
Numerous studies have been undertaken to deter- 
mine the mutational events that are key to particular 
cancers. For colon cancer, it has been shown that the 
same type of tumour can arise through activation of 
different sets ofgenes (3,4). This is also likely to be true 
for other cancers including pulmonary carcinoma. 
Lung cancer is one of the commonest cancers in the 
developed world for both men and women. Prognosis 
is poor with fewer than 13% of all lung cancer patients 
living more than 5 yr after diagnosis [for reviews see 
(5,6)]. With such an appalling mortality it is import- 
ant to elucidate the genetic changes involved in the 
pathogenesis of lung cancer and to determine how 
these changes correlate with clinical features. More 
detailed information may allow earlier diagnosis, 
better tumour typing, more focused treatment and 
improved prognosis. 
Lung cancers are divided into two main groups on 
the basis of their histology (5). The first group, small 
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cell lung cancer (SCLC) accounts for about 25% of all 
lung tumours, is an extremely aggressive neoplasm, is 
frequently associated with distant metastases and has 
the poorest prognosis of all lung tumours. It was for- 
merly treated by surgery, but is now treated primarily 
with chemotherapy and radiotherapy which give 
slightly improved survival rates (7). The second group, 
comprising the remaining 75% of lung cancers, are 
non-small cell lung cancers (NSCLC). There are 
several sub-types which are characterized by their 
tissue of origin: adenocarcinomas which arise in the 
major bronchi, squamous carcinomas which arise in 
the squamous epithelium and large cell carcinomas 
which are largely undifferentiated tumours probably 
arising from stem or basal cells. NSCLC are treated 
primarily with surgery and radiotherapy. SCLC and 
NSCLC are regarded as being separate clinicopatho- 
logical entities on the basis of their morphology, 
sensitivity to chemotherapeutic agents and ionizing 
radiation. They will be treated separately in this review. 
Oncogenes in Non Small Cell Lung Cancer 
RAS 
The K-ras, H-ras and N-ras genes encode highly 
homologous protein monomers, p2 1 Ia, that are located 
on the cytoplasmic side of the plasma membrane. 
Their similarity in sequence to G proteins suggests that 
they may play a role in transmitting proliferation sig- 
nals from receptors at the cell surface to the nucleus 
(8). They bind guanosine triphosphate (GTP) and dis- 
play an intrinsic GTPase activity that is enhanced by 
interaction with the protein, GAP (9). Ras proteins are 
thought to be in an active state for signalling when 
GTP is bound and inactive when the GTP has been 
hydrolysed to GDP (8). Overexpression of the normal 
gene is activating in vitro (8) as are point mutations 
in codons 12, 13 or 61 which prevent intrinsic GTP 
@ 1993 Baillibre Tindall 
414 Topical Review 
hydrolysis presumably by trapping the protein in the 
active form (10). 
Amplification of the ras genes is uncommon in 
NSCLC (1 l-13). One study could find no evidence for 
high levels of overexpression of ras (14) however, 
another group found elevated levels of ~21’“” proteins 
compared to normal adjacent tissue from the same 
patient (15-17). The level and frequency varies with 
the tumour type with about 80% of adenocarcinomas 
compared to 50% of squamous cell carcinomas dis- 
playing increased levels of ras ~21. The exact nature of 
the protein(s) detected is unknown because the mono- 
clonal antibody used (Yl3-259) in these studies neither 
distinguishes between H-, K- and N-RAS proteins nor 
whether the protein is normal or mutant. 
Activating mutations in H-ras and N-ras genes are 
rare in NSCLCs (11,18) except perhaps in Japan (19). 
There is now evidence linking mutations in any mem- 
ber of the ras family with poor prognosis (20). K-ras is 
mutated in approximately 30% of adenocarcinomas, 
but this activation is rare in other types of NSCLC 
(13,21). Several groups have now shown that there is a 
correlation between K-ras mutations in adenocarci- 
nomas and a history of smoking (21-24) with about 
30% of smokers compared with 2% of non smokers 
having G to T transversions at codon 12 (21-23). This 
type of mutation is consistent with exposure of the 
lung to carcinogens in tobacco smoke such as benzo[a] 
pyrene. No correlation was found between K-ras 
mutations and sex, age at diagnosis or tumour stage 
(21), but mutations in K-ras are associated with a very 
poor prognosis (20,21,25). 
MYC 
The myc gene family encodes at least three proteins 
c-MYC, N-MYC and L-MYC, of M, 62-68 kDa. [For 
review see (26)]. The protein products are located in 
the nucleus, bind to DNA and associate with at least 
one other protein, Max (27). The function of MYC 
proteins has not been established, but they may be 
transcriptional factors (28). Activation ofmyc is thought 
to occur by gene amplification or overexpression of the 
protein, but not by point mutations. 
Amplification of the c-myc gene is found in about 
10% and over expression in about 50% of NSCLCs of 
all types (15). L-myc and N-myc appear not to be 
activated in NSCLC although it has been reported that 
N-myc is amplified in a pulmonary adenocarcinoma 
cell line (29). 
Recent RFLP studies have shown that in Japanese 
patients with lung cancer, the form of the L-myc gene 
correlates with prognosis, metastasis and the incidence 
of multiple cancers (30,31). This correlation is particu- 
larly strong for adenocarcinoma and squamous-cell 
carcinoma. However, such correlations were not found 
in studies of Norwegian patients (32) or of white and 
black patients (33). The reason for these contradictory 
results is not known, but may arise from differences in 
the type of tumour analysedpr in the ethnic origin of 
patients. 
ErbB- I 
ErbB-1 encodes the epidermal growth factor recep- 
tor, a transmembrane glycoprotein of M, 170 kDa that 
possesses intrinsic tyrosine kinase activity and is 
though to play a role in signal transduction [for review 
see (34)]. Activation is commonly by overexpression of 
the protein, but not by mutation (35). 
Few studies have been undertaken on the expression 
of erbB-I in lung cancer, but it is reported that about 
25% of squamous SCLCs overexpress erbB-I protein 
(36). 
C-erbB-2 
The c-erbB-2 (neu) gene encodes a transmembrane, 
tyrosine-specific protein kinase, pl 8jneU. It is a putative 
growth factor receptor, related in sequence and struc- 
ture to the epidermal growth factor receptor (37). The 
gene is frequently amplified in adenocarcinomas and 
mRNA and protein levels are frequently elevated in 
tumours as compared to normal tissue. 
Amplification of the c-erbB-2 proto-oncogene is an 
infrequent event in lung cancer (38). However, over- 
expression of ~185”‘” as detected immunohisto- 
chemically, is frequently found in NSCLCs - lo/29 
adenocarcinomas and 5/l 6 squamous cell carcinomas 
(39). In adenocarcinomas, p 185”“” expression tended to 
be found in older patients and there was an independent 
association with short survival times. In squamous cell 
carcinomas, p 185”‘” expression did not correlate with 
these parameters. 
C-FOS AND C-JUN 
clfos and c-&n encode nuclear proteins that form a 
complex, AP- 1, which acts as a transcriptional factor 
for genes possessing a specific DNA recognition site 
(40). Recently, it was reported that in adeno- and 
squamous cell lung carcinomas, the level of AP-1 
activity in nuclear extracts was elevated in ten out of 13 
tumours as compared to their adjacent normal tissues 
(41). As there is evidence that AP-1 may be involved 
in signal transduction (42) elevated levels may be 
oncogenic. It has not been established if changes in the 
AP-1 levels in a tumour correlate with prognosis. 
C-RAF-l 
The c-raf proto-oncogene encodes a serinetthreonine- 
specific protein kinase, ~74”‘.‘, which is located on the 
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internal side of the plasma membrane (43). RFLP 
analyses of 73 unmatched NSCLC tumours showed 
that there was loss of heterozygosity in 31 suggesting 
that this gene might play a role in the pathogenesis of 
the cancer (44). 
C-MYB 
The c-myb proto-oncogene encodes a nuclear pro- 
tein of 75 kDa which is a transcriptional regulator (45). 
DNA hydridization studies showed that three out of 
four adenocarcinomas had lost heterozygosity for 
c-myb (38). Analyses of several NSCLCs have shown 
defects in RNA transcription. Thus in 11 NSCLC cell 
lines no c-myb transcripts were, detected (46). These 
results may indicate that aberrant c-myb expression 
may play a role in generation of lung cancer. 
Onto-suppressor Genes in Non Small Cell Lung 
Cancer 
P53 
The p53 gene encodes a 53-kDa nuclear phospho- 
protein which has recently been identified as a trans- 
criptional activator (47). High levels of the wild type 
gene product inhibit growth possibly through acting as 
a checkpoint for DNA damage at the G&G1 transition 
of cell division (48,49). Several mutant alleles with 
particular single base substitutions encode proteins 
that confer altered cell growth regulatory properties 
(48). 
Mutations in p53 are the commonest genetic 
changes detected in several different types of cancers 
and are a common feature of NSCLCs (50). The 
frequency varies with the type of pulmonary cancer 
with about 67% of squamous cell carcinomas and 37% 
of adenocarcinomas carrying ~53 mutations (51,52). 
Mutations have also been reported in large cell lung 
cancers, three out of six, but the number of cases 
studied was low (52,53). No statistically significant 
correlation has been found between ~53 mutations and 
the age or sex of patients or the histology, clinical 
stage, or lymph node involvement (51). 
G:C to T:A transversions are found in about 50% of 
NSCLCs (5 1,54). This is a type of mutation in ~53 that 
is uncommon in other types of human cancer (50). 
Since one of the components of cigarette smoke is 
benzo[a] pyrene, a potent mutagen that causes G:C to 
T:A transversions (55) a correlation between smoking 
and these particular mutations might be expected. While 
a study of NSCLCs in Japanese patients showed that 
there is indeed a statistically significant association of 
~53 mutations with lifetime consumption of cigarettes 
(5 l), an earlier analysis of ~53 mutations in American 
lung cancer patients found a different nucleotide 
substitution pattern and failed to find any significant 
correlation between smoking and ~53 mutations (52). 
The reasons for these contradictory results are 
unknown. One possibility is that there may be differ- 
ences in the genetic susceptibility to lung cancer in the 
two populations. 
Mutations at many positions along the ~53 gene 
have been found (51,53,56). Codon 273 has been 
reported to be a ‘hot spot’ for mutation in American 
patients with lung cancer, but none of 26 patients 
carried a mutation at this site in a Japanese study (51). 
Immunocytochemical studies have shown higher 
levels of mutant ~53 protein in squamous cell and in 
adenocarcinomas of the lung than in normal adjacent 
tissue (17). The higher the level of ~53 present, the 
poorer was the prognosis both with respect to the pri- 
mary tumour (P< 0.05) and to lymph node metastases 
(P<O.O05) (17). 
p53 alterations have been detected in preneoplastic 
lesions of the lung (57,58) suggesting that ~53 changes 
occur in the early stages of lung cancer development. 
The possibility arises that screening for ~53 mutations 
could form the basis for early detection of lung cancer. 
~53 binds to the product of the MDM2 gene (59) 
which was originally identified as a murine dominant 
transforming oncogene (60). The MDM2 gene maps to 
12q13-14 in man, a chromosomal region that is often 
altered in sarcomas (61). Amplification of the MDM2 
gene is found in over one third of sarcomas (59) and it 
has been suggested that in cancers where only non- 
mutated ~53 can be detected, functional ~53 protein 
may nevertheless be unavailable to the cell by virtue of 
being sequestered by excess MDM2 (59). The status of 
the MDM2 gene in lung cancer will doubtless be the 
subject of intense investigation. 
RB 
The retinoblastoma (Rb-1) gene encodes a DNA 
binding protein of 110 kDa that is thought to be 
involved in events important in cell division (48). 
Inactivation of the Rb gene by deletion and loss of 
heterozygosity have been found in several cancers (48). 
The status of the Rb-1 gene in NSCLC is not known, 
but no alterations were found in 20 NSCLC-derived cell 
lines (62). Anti RBl peptide antibodies precipitated 
RBl protein in eight out of nine NSCLC-derived cell 
lines, so at least in cell lines RBl protein is commonly 
expressed (62). 
NM23 
The nm23 gene located on the long arm of chromo- 
some 17 at 17~1 l-q1 1 (63) encodes a nucleoside 
diphosphate kinase (65). Low levels of nm23 mRNA 
and the corresponding protein have been found to 
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correlate with high metastatic potential in several 
tumours (66,67). Somatic deletion of an allele of nm23 
has been reported in adenocarcinomas of the lung (63), 
but an investigation into its pronostic value showed 
there was no correlation between nm23 product and 
survival rates (68). 
Chromosomal Abnormalities 
The presence of consistent chromosomal losses or 
deletions has suggested the involvement of known or 
candidate tumour suppressor genes at these locations. 
This has been confirmed by RFLP analysis showing 
LOH for genes on chromosomes 13q (RB) and 17p 
(~53) (69). 
The karyotype of NSCLC is complex even in cells 
obtained from tumours prior to chemotherapy (70). In 
one recent study, chromosomes I, 3,6, 7, 8, 11, 13,15, 
17 and 19 were found to carry non random rearrange- 
ments (70). The most frequently rearranged bands 
being 1~13, 3~13, 8pll-qll, lSpll-qll and 17~11 
each of which appeared in 8-14/30 samples. In a differ- 
ent study RFLP deletion analyses of DNA from 53 
primary NSCLCs showed loss of heterozygosity 
(LOH) to be a frequent event on the long arms of 
chromosomes 1 (37%), 2 (31%), 5 (30%), 8 (31%), 
and 13 (32%) and the short arms of chromosomes 3 
(54%) and 17 (62%) (71). LOH on chromosomes 3p 
and 17q were more frequent in squamous- than in 
adenocarcinomas. 
Deletions in the short arm ofchromosome 3 occur in 
over 75% of NSCLCs (72-74). The regions, 3~21.3 
and 3~14. I-21.1 were preferentially deleted in adeno- 
carcinomas and loss of heterozygosity at these regions 
was seen more frequently in poorly- or undifferentiated- 
than in well-differentiated tumours (74). In addition, 
the frequency of deletion was higher in stage III than 
in stage I or II tumours (P = 0.043,). No correlation was 
found with parameters such as smoking status, node 
size and distant metastases. In all squamous cell lung 
carcinomas analysed, there was a deletion at one or 
both of the regions. These results suggest onco- 
suppressor genes may be located at 3~21.3 and 3~14. l- 
2 1.1 and that they may be involved in the progression 
of the tumours. 
Changes in Small Cell Lung Carcinoma 
Mutations in ras genes are essentially absent in 
SCLC - O/42 (75), O/l2 (21) and elevation of ras pro- 
tein expression is rare and not of statistical significance 
(P=O.O7) (17). 
Initial studies on myc expression in SCLC were 
performed on cell lines and found evidence for c-rnyc 
or N-myc gene amplification (16,17) in about 30% of 
cell lines. c-myc amplification was seen only in patients 
who had undergone chemotherapy and a correlation 
between c-myc amplification in treated patients and 
shorter survival times was found (17). 
Gene amplification of all three members of the myc 
family have been observed in primary SCLC (78,79). 
In one study 19/26 patients with metastatic SCLC had 
amplification of either c-myc or N-myc and there 
was no association between mutations and variant 
morphology of tumours. Metastases and tumours had 
similar copy numbers of the genes suggesting that 
myc amplification was an early event. There does not 
appear to be a correlation between the degree of myc 
gene amplification in primary tumour and survival 
time (79). However, it is necessary to interpret these 
results with caution as the survival time of SCLC 
patients after diagnosis is so short anyway. 
In accord with data from cell lines, amplification of 
myc DNA occurs more frequently in patients who 
have undergone chemotherapy, but cell lines estab- 
lished from SCLCs before and after chemotherapy did 
not alter their status of myc gene copy number (80). 
Thus, it is not clear if chemotherapy can actually cause 
myc gene amplification. 
Elevated expression of myc has been observed in five 
of six patient tumours, but the level of expression did 
not necessarily correlate with the degree of myc gene 
amplification (81). In another study of 15 primary 
biopsies from patients who had not undergone chemo- 
therapy, N-myc RNA levels were increased in six cases. 
Increased expression of N-myc correlated with a poor 
subsequent response to chemotherapy, rapid tumour 
growth and short survival times (PcO.01) (82). The 
basis for these observations is not known. 
In a study which included 21 patients with SCLC, 
immunohistochemical analyses showed that c-MYC 
protein was over-expressed in 4 patients. While the 
sample number is low this may be of statistical sig- 
nificance (P < 0.05) (83). The status of c-myc amplifi- 
cation did not correlate with prognosis of the patients. 
RFLP analyses of 84 primary human lung carci- 
nomas indicated LOH for the c-rufl locus in five of 
five informative matched normal and tumour SCLC 
samples and in 42 of 42 unmatched SCLC tumours 
w. 
Onto-suppressor Genes in SCLC 
Mutations in p53 are present in over 75% of SCLCs 
(548486). In one study, loss of one p53 allele and 
mutation of the other was found in 16/ I6 stage III-IV 
tumours and 3/6 stage I-II tumours (85). In addition, 
the allelic loss and/or mutation found in primary 
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tumours was also observed in metastases in distant 
organs suggesting that alterations to ~53 are early 
events in the pathogenesis of SCLC. 
Structural abnormalities within the Rb gene have 
been detected in one of eight (13%) primary SCLC 
tumours and 4/22 (18%) SCLC lines (87,88). Absence 
of RB mRNA and ~105 RB protein however, is 
common in SCLC lines (87,89). 
Deletions of the short arm of chromosome 3 are 
common events in SCLC (90,91) with three distinct 
regions between 3~21-25 being involved (73). Four 
genes, ACY 1, APEH, PTPG and D8 have been cloned 
from this region and their expression in SCLC cell lines 
compared with levels in normal lung (92-95). All are 
under-expressed in at least one cell line, but data are so 
far insufficient to establish a role for any as a tumour 
suppressor gene in SCLC. 
LOH in the tumour suppressor genes, MCC (mutated 
in colon cancer) and APC (adenomatous polyposis 
coli), have been implicated in the pathogenesis of 
several cancers (96-98). Both genes are located on the 
long arm of chromosome 5 (5q21) a region that is often 
deleted in SCLC (99). Over 80% of SCLCs show allelic 
deletion of these genes raising the possibility that they 
are involved in tumourigenesis (100). 
Subtractive hybridization cloning of sequences in a 
lung cancer and normal cell line led to isolation of 
three sequences present in normal, but not in the 
tumour-derived DNA (101). Since one sequence, del- 
118, was also deleted in a freshly isolated lymph node 
metastasis from an adenocarcinoma, it is a candidate 
tumour suppressor gene for lung tumours. 
Concluding Remarks 
Regardless of the tissue or origin, the development 
of a cancer cell from a normal cell involves a series of 
genetic changes that contribute to a loss of normal 
growth control mechanisms. For lung cancer we are 
still far from understanding what these events are. 
Significant progress has been made recently in deter- 
mining the status of oncogenes such as ras and myc and 
onto-suppressor genes such as ~53 whose role is con- 
sidered to be important in the multistep process of 
carcinogenesis. Consistent chromosome deletions may 
facilitate identification of more tumour suppressor 
genes and it is worth noting that microscopically 
visible deletions cover several million base pairs so 
several tumour suppressor genes could be located 
‘close’ together. The expression in lung cancer patients 
of neural cell adhesion molecule and blood group 
antigen A has been linked to favourable prognosis of 
patients (102,103). This presents another promising 
line of investigation. 
Further detailed studies are required to probe re- 
lationships between mutations and factors such as 
diagnosis: clinical parameters: genetic predisposition 
and prognosis. 
In addition, it will be necessary to try to order the 
specific genetic alterations in terms of time as this may 
allow the development of new diagnostic tools, and 
treatments for lung cancer. 
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